The anti-fibrotic effect of bone morphogenic protein- 7(BMP-7) on liver fibrosis

International Journal of Medical Sciences

Volumn 10, Issue 4, 2013, Pages 441-450

  Zhong, Lan ^b   Wang, Xiaolin ^c   Wang, Shenglan ^a   Yang, Li ^a   Gao, Hengjun ^a   Yang, Changqing ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b First Affiliated Hospital of Fourth Military Medical University   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Bone morphogenic protein 7; Epithelial to mesenchymal transition; Extracellular matrix; Hepatic stellate cell; Hepatocytes; Liver fibrosis; Transforming growth factor beta 1

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; RECOMBINANT OSTEOGENIC PROTEIN 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOLOGY; INTRACELLULAR SIGNALING; LIVER CELL; LIVER FIBROSIS; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL; WESTERN BLOTTING;

BONE MORPHOGENIC PROTEIN-7; EPITHELIAL-TO-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX.; HEPATIC STELLATE CELL; HEPATOCYTES; LIVER FIBROSIS; TRANSFORMING GROWTH FACTOR BETA 1;

ANIMALS; BONE MORPHOGENETIC PROTEIN 7; COLLAGEN TYPE I; COLLAGEN TYPE III; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; MALE; RATS; RECOMBINANT PROTEINS; SERUM; SIGNAL TRANSDUCTION; SWINE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84874775926     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5765     Document Type: Article

References (52)

1. Brenner DA, Waterboer T, Choi SK, et al. New aspects of hepatic fibrosis. J Hepatol. 2000;32(1 Suppl): 32-38.
2. Marthinez-Hernandez A, Aamenta P.S. The extracellular matrix in hepatic regeneration. FASEB J.1995;9: 1401-1410.
3. Sato M, Suzuki S, Sonoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct.2003;28: 105-112.
4. Arias E, Anderson RN, Kung HC, et al. Deaths: final data for 2001. Natl Vital Stat Rep.2003;52(3): 1-115.
5. Bauer M, Schuppan D. TGF-β1 in liver fibrosis: time to change paradigms? FEBS Letters.2001;502: 1-3.
6. Breitkopf K, Godoy P, Ciuclan L, et al. TGF-beta/Smad signaling in the injured liver. J Gastroenterology.2006;44(11): 57-66.
7. Chen K, Yang N, Mahato RI. TGF-β1 Gene Silencing for Treating Liver Fibrosis. Mol Pharm.2009;6(3): 772-779.
8. de Gouville AC, Boullay V, Krysa G, et al. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. Br J Pharmacol.2005;145(2): 166-177.
9. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol.2003;38: S38-S53.
10. George J, Roulot D, Koteliansky VE, et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA.1999;96(22): 12719-12724.
11. Gressner AM, Weiskirchen R, Breitkopf K, et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci.2002;1(7): d793-d807.
12. Kim KH, Kim HC, Hwang MY, et al. The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun. 2006;343(4): 1072-1078.
13. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology.2001;120(7): 1784-1800.
14. Qi Z, Atsuchi N, Ooshima A, et al. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA.1999;96(5): 2345-2349.
15. Svegliati-Baroni G, Inagaki Y, Rincon-Sanchez AR, et al. Early response of α2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. Hepatology.2005;42(2): 343-352.
16. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA.1995;92 (7):2572-2576.
17. George J, Roulot D, Koteliansky VE, et al. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA.1999;96 (22):12719-12724.
18. Zhao C, Chen W, Yang L, et al. PPARgamma agonists prevent TGFbeta1/ Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun. 2006;350(2):385-391.
19. Latella G, Vetuschi A, Sferra R, et al. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int. 2009;29(7):997-1009.
20. Higashiyama H, Yoshimoto D, Kaise T, et al. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol. 2007;83(1):39-46.
21. Liu X, Wang W, Hu H, et al. Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm Res. 2006;23(1):82-89.
22. Kaimori A, Potter J, Kaimori JY, et al. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem. 2007;282(30):22089-22101.
23. Dooley S, Hamzavi J, Breitkopf K, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology. 2003;125(1):178-1791.
24. Heidin CH, Miyazono K, Dijke PT. TGFβ signaling from cell membrane to nucleus through SMAD proteins. Nature.1997;390(6659):465-471.
25. Zeisberg M, Bottiglio C, Kumar N, et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse model. Am J Physiol Renal Physiol.2003;285(6): F1060-F1067.
26. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-β1 -induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med.2003;9(7):964-968.
27. Kohji K, Iimuro Y, Otogawa K, et al. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut.2007;56(5): 706-714.
28. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol.2003;284(5): F1006-F1013.
29. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor β in mesangial cells. J Bio Chem.2004;279(22): 23200-23206.
30. Weiner FR, Blaner WS, Czaja MJ, et al. Ito cell expression of a nuclear retinoic acid receptor. Hepatology.1992;15(2): 336-342.
31. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant.2006;21(3):568-573.
32. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem.2007;282(32): 23337-23347.
33. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol. 1976;13: 29-83.
34. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology.1981;1(5):431-435.
35. Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162(1):156-159.
36. rd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.2001;3:15-35.
37. Inagaki Y, Kushida M, Higashi K, et al. Cell type-specific intervention of transforming growth factor beta/Smad signaling suppress collagen gene expression and hepatic fibrosis in mice. Gastroenterology. 2005;129(1):259-268.
38. Abdel Aziz MT, Atta HM, Mahfouz S, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem.2007;40(12):893-899.
39. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med.1993;328(25):1828-1835.
40. Pinzani M. Novel insights into the biology and physiology of the Ito cell. Pharmcol Ther.1995;66(2):387-412.
41. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin PractGastroenterol Hepatol. 2004;1(2):98-105.
42. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol. 2002;3(5):349-363.
43. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest.2007;117(3):524-529.
44. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver int.2006;26(1): 8-22.
45. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res.2003;26(1): 1-9.
46. Gabele E, Brenner DA, Rippe RA. Liver fibrosis: signals leading to the amplification of of the fibrogenic hepatic stellate cell. Front Biosci.2003;8: d69-d77.
47. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell.2003; 113(6):685-700.
48. Wells RG. Fibrogenesis.V. TGF-beta signalling pathways. Am J Physiol Gastrointest Liver Physiol.2000;279(5):G845-G850.
49. Clarke DC, Betterton MD, Liu X. Systems theory of Smad signalling. Syst Biol (Stevenage).2006;153(6):412-424.
50. Clarke DC, Liu X. Decoding the quantitative nature of TGF-b/Smad signaling. Trends in Cell Biology.2008;18(9):430-443.
51. Inman GJ, Nicolás FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3 and 4 permits sensing of TGF-b receptor activity. Mol Cell.2002;10(2):283-294.
52. Lin X, Duan X, Liang YY, et al. PPM1A Functions as a Smad Phosphatase to Terminate TGFβ Signaling. Cell.2006;125(5):915-928.